CoChat
Sign Up
Cited by 45Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial

Open access
Sheline, Yvette I., Snider, B. Joy, Beer, Joanne C., Seok, Darsol, Fagan, Anne M., Suckow, Raymond F., Lee, Jin-Moo, Waligorska, Teresa, Korecka, Magdalena, Aselcioglu, Irem, Morris, John C., Shaw, Leslie M., Cirrito, John R.·2020·Neurology
DOI 10.1212/wnl.0000000000010725PMC PMC7713735
Open this paper in CoChat — free account

Abstract

Objective To determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ42) levels. Rationale Serotonin signaling suppresses Aβ42 in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram. Methods Using lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram × 2 weeks, 20 mg escitalopram × 8 weeks, or 30 mg escitalopram × 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in Aβ42 was used as the primary outcome in subsequent analyses. Results An overall 9.4% greater reduction in CSF Aβ42 was found in escitalopram-treated compared with placebo-treated groups (p < 0.001, 95% confidence interval [CI] 4.9%–14.2%, d = 0.81). Positive baseline Aβ status (CSF Aβ42 levels <250 pg/mL) was associated with smaller Aβ42 reduction (p = 0.006, 95% CI −16.7% to 0.5%, d = −0.52) compared with negative baseline amyloid status (CSF Aβ42 levels >250 pg/mL). Conclusions Short-term longitudinal doses of escitalopram decreased CSF Aβ42 in cognitively normal older adults, the target group for AD prevention. Clinicaltrials.gov identifier NCT02161458. Classification of evidence This study provides Class II evidence that for cognitively normal older adults, escitalopram decreases CSF Aβ42.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000010725

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 30 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sheline, Y. I., Snider, B. J., Beer, J. C., Seok, D., Fagan, A. M., Suckow, R. F., Lee, J.-M., Waligorska, T., Korecka, M., Aselcioglu, I., Morris, J. C., Shaw, L. M., & Cirrito, J. R.
Affiliations
  • Washington University in St. Louis (US)
  • From the Center for Neuromodulation in Depression and Stress, Department of Psychiatry (Y.I.S., D.S., I.A.), and Departments of Radiology (Y.I.S.), Neurology (Y.I.S.), Biostatistics, Epidemiology and Bioinformatics (J.C.B.), and Pathology (T.W., M.K., L.M.S.), University of Pennsylvania, Philadelphia; Department of Neurology, The Knight Alzheimer Disease Research Center, Hope Center for Neurological Disorders (B.J.S., A.M.F., J.-M.L., J.C.M., J.R.C.), Washington University School of Medicine, St...
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2020-11-10
Volume
95
Issue
19
Pages
e2658-e2665
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.0000000000010725
PMC
PMC7713735
OpenAlex
W3086231708
Semantic Scholar
6b4d57833290b19b511813a1f22b4b8259df0b45
Cited by
45
References
30
Citations by year
2026: 4 · 2025: 11 · 2024: 2 · 2023: 8 · 2022: 9 · 2021: 8 · 2020: 3
FWCI
2.66
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (R01AG041502, P50AG005681, P01AG003991, P30AG066444, P01AG026276)
  • National Institute of Neurological Disorders and Stroke (P01NS074969)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
escitalopram, CSF amyloid-beta 42, serotonin signaling, Alzheimer's disease prevention, dose-response relationship, treatment duration, cognitively normal older adults, lumbar puncture
MeSH terms
Duration of Therapy, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Peptide Fragments, Prospective Studies, Citalopram, Cohort Studies, Amyloid beta-Peptides, Selective Serotonin Reuptake Inhibitors, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review